Ad hoc-Mitteilungen

Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access

| Aufrufe: 255

Relief Therapeutics Holding SA / Key word(s): Personnel Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access 17-Aug-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.


Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access

Experienced Leader in Market Access to Bolster Relief’s U.S. Commercial Operations

Geneva, Switzerland, August 17, 2022 RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic benefit from serious diseases with high unmet need, announced today the appointment of David McCullough as Senior Director and Head of U.S. Market Access, effective August 22nd. In this newly created position, reporting to Anthony Kim, Senior Vice President and Head of U.S. Commercial Operations, Mr. McCullough will direct Relief’s market access strategy and operations to ensure timely and effective access to Relief’s products for patients in the U.S.

“David’s appointment as Head of U.S. Market Access signifies an important milestone for Relief, as we have now completed the hiring of the U.S. Commercial Team and are one step closer to providing patient access to treatments for diseases with high unmet medical needs,” stated Mr. Kim. “As we continue to grow, David’s more than 20 years of extensive commercial experience working with payors, physicians and specialty pharmacies to help ensure access for patients and their families, will be invaluable. With expertise and relationships forged during his tenures at Mirum Pharmaceuticals, Inc., Novartis Gene Therapies, Spark Therapeutics and other companies, we look forward to leveraging his broad knowledge of market access in preparation for our October 2022 U.S. launch of PKU GOLIKE®. With continued commercialization of Relief products on the horizon, David serves as a welcome addition to our commercial leadership team.”

Additional features: File: Ad hoc release
End of Inside Information
Language: English
Company: Relief Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Switzerland
Phone: +41 22 545 11 16
E-mail: contact@relieftherapeutics.com
Internet: https://relieftherapeutics.com
ISIN: CH0100191136
Valor: 10019113
Listed: SIX Swiss Exchange
EQS News ID: 1421917
 
End of Announcement EQS News Service

1421917  17-Aug-2022 CET/CEST

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
Kurs:
Relief Therap.
+3,85%
0,027  


Schließen

Spezial!

Noch vor Börsenschluss am Freitagabend positionieren? Heute die letzten Stunden vor einer massiven Veränderung?
weiterlesen»